We recently compiled a list of the 10 Best Non-Tech Stocks to Buy Now for Long Term. In this article, we are going to take a ...

Johnson & Johnson (JNJ) begins on Tuesday its third attempt to push through a multi-billion-dollar settlement relating to ...

Sanctuary Advisors LLC cut its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 10.4% during the fourth quarter, ...

It has been about a month since the last earnings report for Johnson & Johnson (JNJ). Shares have added about 8.9% in that time frame, outperforming the S&P 500. Will the recent positive trend ...

Johnson & Johnson is normally a good buy for its dividend and the stability it offers. Over the past five years, however, the ...

Johnson & Johnson may outshine AbbVie as a top defensive stock pick. Read how Ben Graham's framework evaluates each ...

The latest trading day saw Johnson & Johnson (JNJ) settling at $157.89, representing a +1.87% change from its previous close.

The healthcare leader is also an excellent income stock. Johnson & Johnson has increased its dividend payout for 62 consecutive years, making it a Dividend King. Between Johnson & Johnson's strong ...

KLCM Advisors Inc. grew its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 2.0% in the fourth quarter, ...

If you want upside with a smoother ride than an individual stock, consider the High-Quality portfolio, which has outperformed the S&P, and clocked >91% returns since inception. Johnson & Johnson ...

Pharmaceutical giant Johnson & Johnson (JNJ) is planning to sell its stroke care business called “Cerenovus” for $1 billion ...

Genmab's Q4 2024 results impress with $897.4M revenue and 29% growth. GMAB's balance sheet is strong with nearly $3 billion ...